HK1047288A1 - Compositions for treating inflammatory response. - Google Patents

Compositions for treating inflammatory response.

Info

Publication number
HK1047288A1
HK1047288A1 HK02108948A HK02108948A HK1047288A1 HK 1047288 A1 HK1047288 A1 HK 1047288A1 HK 02108948 A HK02108948 A HK 02108948A HK 02108948 A HK02108948 A HK 02108948A HK 1047288 A1 HK1047288 A1 HK 1047288A1
Authority
HK
Hong Kong
Prior art keywords
compositions
inflammatory response
treating inflammatory
treating
response
Prior art date
Application number
HK02108948A
Other languages
English (en)
Inventor
Joel M Linden
Gail W Sullivan
Ian J Sarembock
Timothy Macdonald
Mark Okusa
Irving L Kron
W Michael Scheld
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/333,387 external-priority patent/US6232297B1/en
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of HK1047288A1 publication Critical patent/HK1047288A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02108948A 1999-02-01 2002-12-10 Compositions for treating inflammatory response. HK1047288A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11802999P 1999-02-01 1999-02-01
US12431699P 1999-03-12 1999-03-12
US13337499P 1999-05-10 1999-05-10
US13557399P 1999-05-24 1999-05-24
US09/333,387 US6232297B1 (en) 1999-02-01 1999-06-15 Methods and compositions for treating inflammatory response
US15141299P 1999-08-30 1999-08-30
PCT/US2000/002324 WO2000044763A2 (en) 1999-02-01 2000-01-31 Compositions for treating inflammatory response

Publications (1)

Publication Number Publication Date
HK1047288A1 true HK1047288A1 (en) 2003-02-14

Family

ID=27557920

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02108948A HK1047288A1 (en) 1999-02-01 2002-12-10 Compositions for treating inflammatory response.

Country Status (26)

Country Link
EP (1) EP1150991B1 (zh)
JP (1) JP4837831B2 (zh)
KR (1) KR100668006B1 (zh)
CN (1) CN1191266C (zh)
AR (1) AR029332A1 (zh)
AT (1) ATE263777T1 (zh)
AU (2) AU778870B2 (zh)
BR (1) BR0007864A (zh)
CA (1) CA2361614C (zh)
CZ (1) CZ296404B6 (zh)
DE (1) DE60009665T2 (zh)
DK (1) DK1150991T3 (zh)
EE (1) EE05185B1 (zh)
ES (1) ES2215609T3 (zh)
HK (1) HK1047288A1 (zh)
HU (1) HU228937B1 (zh)
IL (2) IL144188A0 (zh)
MX (1) MXPA01007850A (zh)
MY (1) MY129445A (zh)
NO (1) NO321216B1 (zh)
NZ (1) NZ513096A (zh)
PL (1) PL199953B1 (zh)
PT (1) PT1150991E (zh)
SK (1) SK284877B6 (zh)
UA (1) UA72912C2 (zh)
WO (1) WO2000044763A2 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CA2460911C (en) * 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US20050033044A1 (en) 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
CN1972945A (zh) * 2004-04-02 2007-05-30 腺苷治疗有限责任公司 A2a腺苷受体的选择性拮抗剂
US7396825B2 (en) * 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7605143B2 (en) * 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
EP2021350B1 (en) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CA2729819C (en) * 2008-07-03 2014-08-26 University Of Virginia Patent Foundation Unit dosage of apadenoson
WO2011002917A1 (en) 2009-06-30 2011-01-06 Pgxhealth, Llc Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2a r agonists
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CN114096552B (zh) * 2019-06-21 2024-09-27 中国人民解放军军事科学院军事医学研究院 具有a2a腺苷受体拮抗作用的小分子化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537228A1 (de) * 1985-10-19 1987-04-23 Huels Chemische Werke Ag Verfahren zur herstellung von cyclohexylverbindungen
JPS6299330A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd 抗高血圧剤
WO1990005526A1 (en) * 1988-11-15 1990-05-31 Yamasa Shoyu Kabushiki Kaisha Agent for treatment and prophylaxis of ischemic disease of heart or brain
EP0429681B1 (en) * 1989-06-20 1995-09-06 Yamasa Shoyu Kabushiki Kaisha (Yamasa Corporation) Intermediate for 2-alkynyladenosine synthesis, production of said intermediate, production of 2-alkynyladenosine from said intermediate, and stable 2-alkynyladenosine derivative
WO1991009864A1 (en) * 1990-01-04 1991-07-11 Yamasa Shoyu Kabushiki Kaisha Drug for treating or preventing ischemic diseases of heart or brain
JPH03287537A (ja) * 1990-03-31 1991-12-18 Yamasa Shoyu Co Ltd 抗動脈硬化症剤
JP3025559B2 (ja) * 1990-07-19 2000-03-27 ヤマサ醤油株式会社 アデノシン誘導体
JP3025557B2 (ja) * 1991-06-28 2000-03-27 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
JP3053908B2 (ja) * 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
AU7449598A (en) * 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
WO1998057651A1 (en) * 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
JPH11335302A (ja) * 1998-05-26 1999-12-07 Toa Eiyo Ltd 安定な医薬組成物
JP3619017B2 (ja) * 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物

Also Published As

Publication number Publication date
SK10972001A3 (sk) 2002-01-07
IL144188A (en) 2008-12-29
EP1150991A2 (en) 2001-11-07
MXPA01007850A (es) 2002-08-20
DE60009665D1 (de) 2004-05-13
JP2002536300A (ja) 2002-10-29
WO2000044763A3 (en) 2000-12-14
EP1150991B1 (en) 2004-04-07
CN1191266C (zh) 2005-03-02
WO2000044763A2 (en) 2000-08-03
MY129445A (en) 2007-04-30
AU2005201255A1 (en) 2005-04-21
IL144188A0 (en) 2002-05-23
NO20013507D0 (no) 2001-07-13
AR029332A1 (es) 2003-06-25
AU2005201255B2 (en) 2008-02-28
BR0007864A (pt) 2001-11-06
KR100668006B1 (ko) 2007-01-15
EE200100397A (et) 2002-08-15
HU228937B1 (en) 2013-06-28
PT1150991E (pt) 2004-08-31
CZ296404B6 (cs) 2006-03-15
CA2361614E (en) 2000-08-03
EE05185B1 (et) 2009-06-15
CN1357002A (zh) 2002-07-03
DK1150991T3 (da) 2004-06-07
AU2745400A (en) 2000-08-18
NZ513096A (en) 2003-01-31
JP4837831B2 (ja) 2011-12-14
DE60009665T2 (de) 2004-08-19
UA72912C2 (uk) 2005-05-16
CZ20012781A3 (cs) 2002-01-16
CA2361614C (en) 2008-08-26
NO321216B1 (no) 2006-04-03
ES2215609T3 (es) 2004-10-16
HUP0200224A2 (en) 2002-06-29
SK284877B6 (sk) 2006-01-05
KR20020013494A (ko) 2002-02-20
HUP0200224A3 (en) 2005-02-28
ATE263777T1 (de) 2004-04-15
AU778870B2 (en) 2004-12-23
CA2361614A1 (en) 2000-08-03
NO20013507L (no) 2001-09-18
PL199953B1 (pl) 2008-11-28

Similar Documents

Publication Publication Date Title
HK1047288A1 (en) Compositions for treating inflammatory response.
GC0000114A (en) Celecoxib compositions.
ZA200107596B (en) Multiple component bleaching compositions.
ZA200108687B (en) Enhanced herbicide compositions.
HK1046647A1 (en) Compositions for improving fertility.
AU5294100A (en) Method and compositions for treating the inflammatory response
GB9917976D0 (en) Herbicidal compositions
MXPA01013312A (es) Composiciones antibacterianas.
MXPA02005067A (es) Composicion inhibidora de la corrosion.
GB9921037D0 (en) Compositions
ZA200107194B (en) Detergent compositions.
ZA200107863B (en) Candle composition.
GB9904049D0 (en) Rapidly-soluble compositions
ZA200109900B (en) Cleaning compositions.
ZA200108893B (en) Fungicidal compositions.
ZA200005697B (en) Paroxetine compositions.
ZA991892B (en) Herbicidal compositions.
ZA200108844B (en) Fungicidal compositions.
GB9929622D0 (en) Compositions
ZA200204077B (en) Scouring composition.
ZA200202814B (en) Cast detergent composition.
GB9903924D0 (en) Cosmectic compositions
GB9904931D0 (en) Compositions
GB9926833D0 (en) Compositions
ZA997477B (en) Novel composition.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180131